Systematic Quantum Tunneling Analysis of FDA-Approved Enzyme Drug Targets Reveals 35.7% Are Quantum-Critical: Implications for Rational Drug Design

Key Points

• To analyze the quantum tunneling dependence in FDA-approved enzyme drug targets and identify quantum-critical targets.
• Systematic computational analysis using the MEG-APSU Lindblad quantum dynamics solver
• Evaluated 89 FDA-approved enzyme drug targets
• Classified targets using quantum tunneling metrics
• Achieved 100% classification accuracy across training and validation sets
• Assessed correlation of quantum-critical status with withdrawn drugs
• 41 out of 115 FDA-approved enzyme targets identified as quantum-critical (35.7%)
• Cohen's d = 5.833 for training, indicating a strong effect size
• Cohen's d = 4.401 for blind validation, also showing a strong effect size
• ROC AUC of 1.000 reflects perfect classification accuracy
• Odds ratio of 33.9 for withdrawn drugs correlated with quantum-critical targets